## Section 2. Documentation Requirements

### 2.1 Essential Documents

The DAIDS policy on Requirements for Essential Documents at Clinical Research Sites Conducting DAIDS Funded and/or Sponsored Clinical Trials and E6 Good Clinical Practice: Consolidated Guidance specifies the essential documents that study sites must maintain. The Division of AIDS (DAIDS) Site Clinical Operations and Research Essentials (SCORE) Manual also contains information on best practices for essential documents. Although all required documentation must be available for inspection at any time, all documents need not be stored together in one location.

Suggested essential documents filing structure is available upon request from FHI 360. Study sites are not required to adopt the suggested structure but are encouraged to consider it when developing their filing approach for the study. Further clarifications of the suggested filing structure are as follows:

- **Essential documents may be stored in files and/or in binders.** The files/binders listed in essential documents filing structure may be further subdivided, consolidated, and/or re-organized.  
  - **NOTE:** Sites that chose to file documents electronically must ensure computer systems are 21 CFR Part 11 compliant and are required to have documentation on file certifying that their systems meet such requirements. Refer to the MTN Manual of Operational Procedures, Section 9, for further details on the requirements that must be met when using electronic systems/software.
- **It is recommended that a contents sheet be maintained and inserted as the first page(s) of each file/binder.** Within each file/binder, it is recommended that documents be filed in ascending date order (most recent documents in front).
- **Certain documents related to the investigational study products will be stored in site pharmacies.** A listing of essential documents to be maintained in the pharmacies is provided in Section 2.3.

To facilitate routine inspection by study monitors, certain laboratory-related essential documents should be stored in the main study essential documents files/binders. Other lab-related essential documents (e.g., lab SOPs) may be filed in site laboratories.

- **The suggested filing structure assumes that MTN-034 participant research records will be stored separately from the other essential documents.** Section 2.2 below provides information on the required contents of these records.

---

### Table: Suggested essential documents

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>Essential Documents</td>
<td>2-1</td>
</tr>
<tr>
<td>2.2</td>
<td>Participant Research Records</td>
<td>2-2</td>
</tr>
<tr>
<td>2.3</td>
<td>Financial Disclosure Forms</td>
<td>2-2</td>
</tr>
<tr>
<td>2.4</td>
<td>Required Source Documentation</td>
<td>2-3</td>
</tr>
<tr>
<td>2.5</td>
<td>Chart Notes</td>
<td>2-4</td>
</tr>
<tr>
<td>2.6</td>
<td>Visit Checklists</td>
<td>2-4</td>
</tr>
<tr>
<td>2.7</td>
<td>Laboratory</td>
<td>2-5</td>
</tr>
<tr>
<td>2.8</td>
<td>Case Report Forms (CRFs)</td>
<td>2-5</td>
</tr>
<tr>
<td>2.9</td>
<td>Protocol Deviations</td>
<td>2-6</td>
</tr>
<tr>
<td>2.9.1</td>
<td>Protocol Deviations Related to COVID-19</td>
<td>2-7</td>
</tr>
<tr>
<td>2.10</td>
<td>Document Organization and Participant Confidentiality</td>
<td>2-7</td>
</tr>
<tr>
<td>2.11</td>
<td>Study Product Accountability, Chain of Custody, and Dispensing</td>
<td>2-8</td>
</tr>
<tr>
<td></td>
<td>Documentation in the Pharmacy</td>
<td></td>
</tr>
<tr>
<td>2.12</td>
<td>Translation Procedures</td>
<td>2-8</td>
</tr>
<tr>
<td>2.13</td>
<td>Record Retention Requirements</td>
<td>2-9</td>
</tr>
</tbody>
</table>
The MTN-034 Screening and Enrollment Logs and PTID-Name Linkage Log must be maintained in hard-copy. The suggested filing assumes that these logs will be stored in the study clinic or data management area throughout the screening and accrual process and not necessarily with the other essential documents listed.

All significant communications between the study sponsor and/or management team and study sites should be printed and filed with other essential documents.
- All site responses to priority emails (thereby indicating they were read and responded to)
- All study management team and/or sponsor communications that document agreements or significant decisions involving trial administration or conduct, protocol deviations, eligibility and informed consent, safety and/or study endpoints, or study product
- All notifications of critical events (CE) that are submitted to the DAIDS
- Protocol Team call slides and/or supplemental materials
- Final training reports, including sign-in sheets
- Final study activation notification memo and activation checklist
- Final reports from assessment visits conducted by FHI 360, or others on the study management team as well as the completed list of action items stemming from the report
- Emails and other key communications (e.g., Operational Guidance) from the study management team that specify to print and file

Note: When required documents are modified or updated, the original and all modified or updated versions must be retained. Communications that are participant identification (PTID)-specific should be printed and filed in the participant binder. Communications that are not PTID-specific can be printed and filed in regulatory documentation. All clinical site monitoring reports and correspondence can be accessed through the DAIDS-ES system within the NIAID Clinical Research Management System and do not need to be printed and filed.

2.2 Participant Research Records

Study sites must maintain adequate and accurate participant research records containing all information pertinent to MTN-034 for each study participant. See Protocol section 13.6 for further information regarding all participant information which should be stored in locked file cabinets with access limited to authorized study staff.

The International Conference on Harmonization (ICH) Consolidated Guidance for Good Clinical Practice (GCP) defines the terms source data and source documentation as follows:

- The term source data refers to all information in original records and certified copies of original records related to clinical findings, observations, or other activities in a clinical study necessary for the reconstruction and evaluation of the trial (including all screening, enrollment and randomization activities). Source data are contained in source documents (e.g., original records or certified copies).

- The term source document refers to original documents, data, and records (e.g., hospital records; clinical and office charts; laboratory reports or logs; memoranda; participants’ diaries and/or evaluation checklists; pharmacy dispensing records; recorded data from automated instruments; copies of transcriptions certified after verification for accuracy and completeness; microfiche; photographic negatives; microfilm or magnetic media; x-rays; participant files; and records kept at the pharmacy, laboratories, and medico-technical departments involved in the study).

Source documents are commonly referred to as the documents—paper-based or electronic—upon which source data are first recorded. All study sites must comply with the standards of source documentation specified in the DAIDS Site Clinical Operations and Research Essentials (SCORE) Manual (https://www.niaid.nih.gov/research/daids-score-manual).

2.3 Financial Disclosure Forms
Each clinical investigator listed on the Form 1572 must disclose any financial interests that may be affected by the outcome of the research or attest to the absence of relevant significant financial interests. Per 21 CFR 312.53, financial disclosure must be completed prior to study involvement. The IoR and site Regulatory Coordinator must ensure that prior to completing (adding or removing investigators) and prior to the IoR signing the FDA Form 1572, all investigators listed on the form must complete and sign the study-specific financial disclosure form (FDF). In addition, investigators listed on the current FDA Form 1572 must submit a new FDF at the completion of all study-specific activities (i.e. the date of the last participant follow-up visit at the study site).

A blank FDF is available on the MTN-034 webpage. All items can be entered electronically except for the signature and date. The ‘Study start date’ is date on the cover of the most current version of the protocol. The ‘Study end date’ is the date of last follow-up at the site; this section on the FDF form may be left blank until the end of follow-up at the site.

At the beginning of the study and throughout study duration, whenever an FDF is completed, sites should upload the form to the DAIDS Protocol Registration System (DPRS), under the “Other” submission category. Training slides on the requirements for FDF completion can be found here: http://www.mtnstopshiv.org/node/1639

2.4 Required Source Documentation

For MTN-034, participant research records should consist of the following source documents:

- Chart notes
- Documentation that the participant provided written informed assent/consent and/or parent/guardian permission to screen for and participate in the study prior to the conduct of any study procedures
- Documentation that the participant met the study’s eligibility criteria
- A record of the participant’s use of the investigational study products
- Pharmacy investigational product dispensing and chain of custody records (maintained in the study site pharmacy), as well as clinic study product accountability documentation (maintained in the study clinic)
- A record of all contacts, and attempted contacts, with the participant
- A record of all procedures performed by study staff during the study (e.g. on visit checklists and/or other site-specific procedural flow sheets or chart notes)
- Local laboratory testing logs and result reports, or other as defined as a source document for a test result.
- Case report forms (CRFs) and other forms provided by the MTN SDMC, RTI or MTN LOC
- Study-related information on the participant’s condition before, during, and after the study, including:
  - Data obtained directly from the participant (e.g., interview and/or other self-reported information)
  - Data obtained by study staff (e.g., exam and lab findings)
  - Data obtained from non-study sources (e.g., non-study medical records)
  - Other source documents (e.g., site-specific worksheets)

As a condition for study activation, each study site must establish an SOP for Source Documentation that specifies the source documents for all study procedures. To establish consistency in source documentation across sites, the recommended source for specific study procedures will be provided within the Source Documentation SOP template. Supplemental information on the use of chart notes, visit checklists, and forms provided by the MTN SDMC or MTN LOC is provided below. Detailed information on proper completion, maintenance, and storage of participant product dispensing documentation is provided in SSP Section 6, and the MTN-034 Pharmacist Study Product Management Procedures Manual. Detailed information on proper completion of CRFs is provided in the MTN-034 CRF Completion Guidelines provided by the MTN SDMC. Detailed information on proper behavioral research procedures is provided by RTI in SSP Section 11.
2.5 Chart Notes

Study staff must document every contact with a study participant in a signed and dated chart note or contact log specifying the following information:

- Visit date at which a contact or procedures takes place
- Visit type (scheduled, interim, etc.)
- Purpose of the visit and location of the contact if other than the research clinic
- General status of the participant at the time of the visit

Chart notes also should be used to document the following:

- The informed consent and assent processes (if an Informed Consent or Assent Coversheet is not used)
- Procedures performed that are not recorded on other source documents
- Additional information related to clinical exam findings to ensure appropriate follow-up
- Study-specific counseling sessions and any associated referrals that are not documented on other source documents
- Other pertinent data about the participant that are not recorded on other source documents
- Reason(s) why protocol-specified procedures were not performed
- Contact attempts to follow up on participants who missed a scheduled study visit

2.6 Visit Checklists

Visit checklists are convenient tools which may serve as source documentation if designed and completed appropriately. These checklists alone may not be sufficient for documenting all procedures but can be used to indicate that the procedure was completed. Chart notes may be required to supplement the information recorded within visit checklists. Visit Checklist templates are available on the MTN-034 website.

Tips for completing visit checklists in accordance with these requirements are as follows:

- Enter the participant identification (PTID) number and visit date on the top section of each checklist. If checklists are multiple pages, enter the PTID and visit date on each page.
  - For screening visits, write the screening attempt number in the applicable checklist item.
  - For follow-up visits, enter the visit code/number on the top section of each checklist.
- Enter your initials only beside the procedures that you perform. Do not enter your initials beside procedures performed by other staff members.
- Ideally, only one person should initial each line of the checklist. If the line includes multiple procedures and they are performed by different staff, indicate who performed which procedure in the comments. Checklists should be designed to avoid this practice.
- If all procedures listed on a checklist are performed on the date entered in the top section of the form, the date need not be entered beside each item. If procedures listed on a checklist are performed on multiple dates, enter the date upon which each procedure is performed beside each item.
- For items on the checklist that contain checkboxes, one set of initials is still sufficient, even if multiple boxes are checked.
- If a procedure listed on the checklist is not performed, enter “N/D” for “not done” beside the item and record the reason why on the checklist (if not self-explanatory); initial and date this entry.

The sequence of procedures presented on the template visit checklists is a suggested ordering. In consultation with the MTN LOC (FHI 360), site staff should modify the checklists to maximize the efficiency of site-specific study operations. Visit checklists, and visit flow, should be monitored and updated as needed to ensure that study visits are completed as quickly as possible, with minimal
delays for participants and study staff. Sites may alter the sequence of procedures to suit local staffing and logistical requirements, with the following exceptions:

- Written informed consent/assent and parental permission must be obtained before any study procedures are performed.
- On the day of enrollment, randomization must take place after confirmation of eligibility and collection of blood for plasma archive.
- It is recommended that for sites not doing finger stick HIV testing, blood for HIV serology and plasma archive are collected together, to limit venipuncture to a single blood draw. If a participant is subsequently found to be ineligible and is not enrolled, the plasma archive sample should be destroyed.
- The Visit 2 (Enrollment) ACASI Questionnaire may be done before or after randomization but must be completed prior to provision of study product and first dose or ring insertion.
- Any laboratory testing that is intended to be performed rapidly in the clinic, such as hCG and HIV testing, should be performed and results provided to the participant prior to study product provision or the participant leaving the clinic. Additionally, clinicians should review the hCG and/or HIV test results prior to the clinical examinations and further specimen collection (i.e., pelvic samples) to ensure no procedures need to be modified in the case of a positive result.
- Pelvic exam procedures must be performed in the sequence shown on the pelvic exam checklists at visits where a pelvic exam is required. For clinically indicated pelvic exams, procedures may be documented in the chart notes and/or the Pelvic Exam checklist.
- During follow-up, behavioral assessments (including ACASI questionnaires) should be administered after pregnancy testing, but prior to the HIV/STI risk reduction, product use and protocol adherence counseling.
- It is recommended that procedures for determining eligibility for continued product use be conducted early in the visit to ensure that these procedures are conducted if the participant needs to abruptly leave the clinic or is short of time.
- For those in the vaginal ring (VR) use period, VRs should be removed immediately upon identification of conditions which require a hold or discontinuation. Otherwise, timing of VR removal depends on whether a pelvic exam is being conducted:
  - At follow-up visits without pelvic exams, it is recommended that participants are asked not to remove current vaginal ring (VR) until immediately prior to vaginal swab self-collection, and after provision of a new VR for insertion.
  - At follow-up visits with pelvic exams, it is recommended that clinicians remove the VR at the beginning of the pelvic exam (or have participants remove the current VR immediately prior to the pelvic exam). Provision of a new VR for insertion should occur after the exam.

### 2.7 Laboratory

Each lab test must have a defined source document which is the first place the result is recorded or generated. Site laboratories will have a plan for the storage of these documents so that they are easily retrievable.

### 2.8 Case Report Forms (CRFs)

The CRFs for this study are designed for use with the Medidata Rave clinical data management system. As specified in the Source Documentation SOP template, CRFs are designed to be used as source, whenever possible. Prior to study activation, each study site will document the eCRFs to be used as source documents, eCRFs that will not be used as source, and specify non-eCRF source documents in its SOP for Source Documentation. The specifications of this SOP must be followed consistently for all study participants. If study staff are not able to record data directly onto forms designated as source documents, the following procedures should be undertaken:

- Record the data onto an alternative source document
- File the alternative source document into the participant’s study chart
• Transcribe the data from the alternative source document onto the appropriate form and enter a note on the form stating the alternate source document used
• Write a chart note stating the relevant study visit date and the reason why an alternative source document was used
• Perform QC procedures as specified in the site-specific Data Management SOP to ensure accurate and correct data transcription

2.9 Protocol Deviations

DAIDS requires that all protocol deviations be documented in participant records, along with efforts made to correct the deviations, and efforts made to prevent similar deviations in the future. The MTN Manual of Operational Procedures (MOP) should be referenced for complete guidance on protocol deviations.

For MTN-034, the Protocol Deviation Log CRF will be used to document each protocol deviation. The Protocol Deviation Log CRF is completed and submitted to the MTN SDMC for each reportable deviation identified. Corrective and preventive action plans are required components of protocol deviation documentation. It is important to ensure that chart notes or other source documents include any associated counseling that was done to address the protocol deviation. Note that the corrective and preventive actions must be documented, but are not required to be completed, prior to reporting the deviation to SCHARP. The Protocol Deviation Log CRF should be submitted upon identification of the deviation, even if all the actions/plans are still in-progress.

Missed visits are considered protocol deviations per the MTN policy, however these will not be captured on the Protocol Deviation Log CRF. The Missed Visit CRF will capture this information instead. Also, study product non-use is not considered a reportable protocol deviation in REACH; however, laboratory-based drug level results (e.g. residual drug levels in used VRs and dried blood spot PK analysis by Truvada users) will be captured on applicable CRFs. Refer to the CRF Completion Guidelines for a detailed description of each applicable PD for REACH.

Protocol deviations should be reported within 7 days of site awareness. If there is a question as to whether a deviation has occurred, or how it should be documented, the MTN Regulatory Department and the Study Management Team should be contacted at mtnregulatory@mtnstopshiv.org and mtn034mgmt@mtnstopshiv.org. Once the potential protocol deviation has been confirmed, the site will be contacted with this confirmation and the 7-day reporting requirement will begin. Once the CRF is submitted, SCHARP will follow up with the site if any clarifications or additional information on the CRF is needed.

It is recommended that all PDs occurring at the site be submitted to the local IRBs/ECs in accordance with their reporting policies. Some PDs may need to be reported in real time (e.g. those with a potential impact on participant safety) while others can be submitted as part of a summary listing later. If a local IRB/EC does not have a specific reporting policy, the MTN recommends that a full listing of study protocol deviations be submitted at the time of IRB/EC renewal submission, annually per local requirements. These listings may be provided by the MTN SDMC to the sites upon request.

If a significant deviation is identified as part of a PPD monitoring visit, the site will need to provide corrective and preventative action (CAPA) to their Office of Clinical Site Oversight (OCSO) Program Officer (PO) through the clinical site monitoring (CSM) system to close out the monitoring findings. The MTN-042 study management team should also be notified of significant deviations and associated CAPAs.

If a significant deviation is identified by the site or protocol team, the event no longer needs to be reported to the OCSO PO for determination of critical events status (policy obsoleted) and should be managed by the study management team including review and approval of a CAPA and assuring reporting to IRB/EC and other regulatory bodies as needed. Significant deviations are described in the MTN-042 risk mitigation plan and include:

• Inappropriate Enrollments
• Informed Consent Deviations
• Study Product Management Deviations
• Unreported or delay in reporting SAE/EAEs

2.9.1 Protocol Deviations Related to COVID-19

In order to track COVID-19 related impacts in real time, sites are requested to report all COVID-related changes to study implementation as protocol deviations, regardless of whether a deviation has occurred. Protocol deviations related to COVID-19 should be reported as follows:

• For any visit that is modified due to COVID-19 (i.e. remote visits, split visits, missed procedures, study product delivery, etc.), a protocol deviation should be reported immediately, even if remaining procedures are expected to be completed at a later date
• One protocol deviation report per participant per study visit is acceptable
• In the event a split visit occurs, do not modify or remove these reported PDs at a later date. Refer to the Data Collection SSP section 12 on how to complete visit dates for split visits.
• For any missed visits that occur due to COVID-19, staff should complete a Missed Visit CRF per standard practice. For the “Reason visit was missed” mark “Other” and note “Due to COVID-19” in the ‘If “Other”, specify’ text box. If you have a question as to whether a missed visit is related to COVID-19, please contact SCHARP and FHI 360 to confirm.

COVID-19 related protocol deviation reporting is for tracking purposes only and does not count toward site metrics or reviews of site implementation quality. However, these PDs represent deviations from the protocol to eliminate an immediate hazard to trial participants without prior IRB/EC approval. Per the ICH E6(R2), Section 4.5.4, COVID-19 related PDs should be submitted as follows:
• To the IRB/IEC for review and approval/favorable opinion;
• To the sponsor for agreement and, if required;
• To the regulatory authority(ies)

2.10 Document Organization and Participant Confidentiality

Study staff must make every effort to store all study records securely and confidentially. Case history records must be stored in the same manner for all participants, in areas with access limited to authorized study staff only. Study staff are responsible for purchasing file folders, binders, storage cabinets, and any other equipment or supplies needed to properly store all records.

Study-related documentation collected during the screening process should be stored in a file folder/binder for each potential participant. All screening documentation — for potential participants who eventually enroll in the study as well as for those who do not enroll or “screen out” — must be maintained and available for monitoring throughout the study. This documentation also must be available for reference should participants present to the site for re-screening. For participants who enroll in the study, screening documentation should be transferred to a separate file folder/binder that will serve as participants’ study notebook for the duration of their participation in the study.

All documents contained in participant case history records must bear a participant identifier, which generally will consist of either the PTID number or the participant name. The PTID should be used whenever possible to maximize participant confidentiality. As a best practice, it is recommended that records bearing names or other personal identifiers, such as locator forms and informed consent forms, are stored separately from records identified by PTID. Any documents transferred or transmitted to a non-study site location must be identified by PTID only. Care should also be taken to only refer to participants by PTID in email communication when people outside of the CRS are included.

Regardless of whether the identifier on a document consists of the participant name or PTID, the original identifier may not be obliterated or altered in any way, even if another identifier is added. When necessary to maintain confidentiality, identifiers may be obliterated on copies of original source documents. For example, if medical records obtained from a non-study health care provider bear the participant’s name, the original documents bearing the name must be stored unaltered with other study documents bearing the name. However, a copy of the original documents could be made, the PTID could be entered onto the copies, and then the participant name could be obliterated from the
copies. Copies handled in this way could then be stored in participants’ study notebooks and/or transferred or transmitted to non-study site locations.

All on-site databases and ACASI questionnaire data must be secured with password protected access systems. Any lists, appointment books, or other documents that link PTIDs to other participant identifiers (such as the PTID-Name Linkage Log) should be stored securely (locked cabinet/drawer if hard copy; password protected if electronic) and it is recommended in a location separate from individual participant records (that identify participant by either PTID or name). When in use, documents that link PTIDs to other participant identifiers should not be left unattended or otherwise accessible to study participants, other study clinic patients, or any other unauthorized persons.

2.11 Study Product Accountability, Chain of Custody, and Dispensing Documentation in the Pharmacy

Pharmacy staff will document the receipt and dispensing of each study product and destruction of each unused study product. Separate accountability records must be maintained for each product, per instructions provided in the MTN-034 Pharmacist Study Product Management Procedures Manual available from the MTN Pharmacist.

Pharmacy staff also will maintain in the study pharmacies a Participant-Specific Pharmacy Dispensing Record for all enrolled study participants, per instructions in the MTN-034 Pharmacist Study Product Management Procedures Manual. Study clinic staff will contribute to the documentation of product provision and chain of custody as described in Section 6 of this manual.

The specifications related to document security and participant confidentiality described in Protocol section 13.6 also apply to records maintained in the study pharmacies. All records must be stored securely in the pharmacies with access limited to authorized study pharmacy staff only.

The following essential documents should be maintained in study site pharmacies:

- Current MTN-034 Protocol
- Investigator’s Brochure for Dapivirine Vaginal Ring: current version and any subsequent updates
- Package Insert for Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada): current version and any subsequent
- Current FDA Form 1572
- Current list of authorized prescribers and staff authorized to sign Study Product Request Slips (names and signatures)
- Pharmacy Establishment Plan (PAB or MTN LOC Pharmacist approved)
- MTN-034 Pharmacist Study Product Management Procedures Manual and applicable SOPs for investigational study product management, dispensation and accountability
- MTN-034 SOP for product Chain of Custody
- MTN-034 product shipping and receipt documentation, product storage temperature logs, and investigational product accountability records
- MTN-034 participant-specific records (including prescriptions and request slips, participant-specific dispensing record, record of receipt of participant study product and documentation of unused product returns)
- MTN-034 monitoring visit reports
- MTN-034 communications with site clinic staff, communications with the MTN Pharmacist, iPMT Clinical Supply Coordinator and/or TCG (product distributor)
- MTN-034 communications with the MTN LOC and/or the MTN SDMC or other MTN-034 communications or locally required administrative, operational, and/or regulatory documentation

2.12 Translation Procedures
Per the MTN MOP Section 11, all study materials that are read verbatim or provided to the participant must be translated into local language, back-translated, and reviewed by members of the study management and/or behavioral team as appropriate. Participant materials include the informed consent and assent forms and comprehension assessments, interviewer-administered CRFs, ACASI questionnaires, qualitative interviews and focus group scripts, and other study materials developed for participant use.

- Site teams are responsible for establishing a site-specific translation SOP that should minimally contain the following elements:
  - Description of the translation and back-translation process, and quality control procedures
  - Who is responsible for conducting each step of this process (and whether is occurring on-site staff or through a contracted group)

All staff members involved in the translation and back-translation process should ensure that language fluency is documented on their CV on file at the research site and this responsibility is assigned per the site Delegation of Duties Log. A standard Certificate of Translation should be issued for translations conducted, indicating the specific documents that were translated (with version number/date as appropriate) as well as the individual conducting the translation. It is recommended that as part of translation procedures, staff members who will be responsible for utilizing the translated study materials review and/or pilot use of the tool to confirm translations are understandable in the context they will be used.

### 2.13 Record Retention Requirements

All study records must be maintained for at least two years following the date of marketing approval for the study product for the indication in which they were studied. If no marketing application is filed, or if the application is not approved, records must be retained for two years after the US Food and Drug Administration is notified that the Investigational New Drug application for the product(s) is discontinued.

All records must be retained on-site throughout the study’s period of performance, and for at least three years after completion or termination of the study. Study product records must be stored in site pharmacies, with access limited to authorized study pharmacy staff only. Study records should not be re-located to an off-site location or destroyed without prior approval from the MTN (see section 18 of the MOP).